The Physician Executive has his thoughts, but I think the reason is much simpler. Repackaging two cheap, generic medications into an expensive, brand-name pill is generally not a good business model for success.
Related Stories
More in Uncategorized
Comments
Previous post: Vytorin, the "besmirched drug du jour"
Next post: Where do you stand on health care?
